BAT's Velo Surge Challenges Philip Morris' Zyn Premium as FDA Fast-Track Looms

The U.S. nicotine pouch market is on a steep growth path, with the category valued at USD 8.6 billion in 2025 and projected to reach USD 9.9 billion in 2026. The long-term trajectory is even more dramatic, with forecasts pointing to a CAGR of 19.4% through 2035. This expansion is fueled by a clear consumer shift away from traditional tobacco products, seeking cleaner, more discreet alternatives.

At the center of this growth is a fierce battle for market share. Philip Morris International led with over 26% market share in 2025, powered by its Zyn brand. However, the competitive landscape is rapidly intensifying. British American Tobacco's (BAT) Velo brand is emerging as a major challenger, capturing a significant portion of the category's expansion. Jefferies noted that BAT captured roughly two-thirds of category growth in late 2025, signaling a direct and aggressive push to displace the market leader.

This heightened competition is beginning to moderate growth expectations. While the category remains robust, the pace is expected to slow. Jefferies now expects U.S. pouch volumes to grow about 12% in 2026, a figure that sits well below the Street's consensus forecast of about 20%. The brokerage attributes this downward revision to the intensified competition and the looming threat of new entrants, such as BAT's potential FDA fast-track approval for Velo products. For Philip Morris, which relies on pouches for a key valuation support, this shift marks a critical inflection point where growth momentum is being tested by a more crowded and aggressive field.

Company-Specific Supply and Demand Dynamics

The growth story for the U.S. nicotine pouch market is now being played out through the operational and financial performance of its key players. For Philip Morris International, the demand for its Zyn brand is the primary engine driving its forward-looking profit outlook. The company has forecast double-digit profit growth for 2026, a projection directly tied to the high-margin success of its smoke-free products in the United States. This financial strength is built on a foundation of massive cash generation, with smoke-free products contributing over 41% of total net revenues in 2025. Yet, this growth is occurring against a backdrop of a tightening competitive landscape, as rivals like British American Tobacco aggressively capture share. . The pressure is real, and it tests the durability of PM's growth forecast.

British American Tobacco presents a different dynamic, one of a company successfully capturing new demand. Jefferies analysts describe BAT as an underappreciated Smoke-Free improver, citing the major success of its Velo brand in the U.S. and Europe. This isn't just incremental growth; it's market share gain that is reshaping the competitive balance. The company's robust financial health, evidenced by strong operating margins and a solid balance sheet, provides the firepower to fund this expansion and support substantial cash returns for shareholders. This operational momentum is what makes BAT the sector's top pick.

This shift in company fundamentals is mirrored in the broader market's valuation. The entire tobacco sector has undergone a significant re-rating, moving from a 12x to 15x price-to-earnings multiple over the past two years. This re-rating reflects a growing recognition of the cash-generating power and growth potential within the smoke-free segment. Both Philip Morris and British American Tobacco now offer investors mid-single to high-single digit dividend yields, supported by rising share buybacks. The setup is clear: supply and demand are being met by companies with the financial wherewithal to invest, but the path for each is distinct. PM's growth is being challenged by competition, while BAT's improving fundamentals are being rewarded by the market.

Valuation and Forward Catalysts

The current valuation of the U.S. nicotine pouch market is being tested by a clear divergence between growth expectations and competitive pressures. For Philip Morris International, the math is tightening. The stock now trades near a 21x earnings multiple, a premium that Jefferies argues has capped further multiple expansion. The brokerage's recent downgrade to Hold from Buy hinges on this high entry price and a belief that the company's growth momentum in oral nicotine pouches will slow in 2026. Jefferies sees limited re-rating potential next year given intense competition and has cut its 2026 earnings estimate. This sets up a valuation challenge: the stock's support depends on sustained execution, but the path to a re-rating appears blocked by a crowded field.

The most immediate catalyst-and a source of risk-is regulatory. A positive outcome from the FDA fast-track pilot for oral nicotine pouches could allow British American Tobacco to introduce its Velo products in the U.S. as early as 2026. This would directly intensify the competitive battle for Zyn's market share, potentially accelerating the growth slowdown Jefferies already anticipates. For now, the category's growth remains robust at over 35%, but the pace is expected to moderate to about 12% in 2026, a figure that sits well below the Street's consensus. This creates a setup where valuations are being asked to hold on to high expectations despite a more competitive and potentially slower-growth reality.

Altria Group's position is more defensive, focused on cash returns than market share. The company is expanding its 'on!' pouch brand nationally, a move that widens retail access. Yet the sector's overall growth is expected to be modest, and Altria's own numbers show the category's impact is still limited. Its oral tobacco product revenue grew less than 1% last year, a figure that slows from prior growth. For Altria, the expansion is a step in a long-term pivot, but it's not a growth lever. The stock's appeal lies elsewhere: its forward-looking dividend yield of 6.7% offers reliable income as the company manages the slow wind-down of its core cigarette business. In this context, valuation is less about growth re-ratings and more about the durability of that cash return.

The bottom line is that the market's high valuations for these players are now contingent on navigating a sharper competitive landscape. Philip Morris must defend its premium, while Altria's strategy is to generate income from a shrinking base. The FDA fast-track pilot for Velo products is the clearest near-term catalyst, one that could disrupt the balance of power and further test the growth assumptions underpinning current prices.